These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33590445)

  • 21. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    Nguyen DT; Tran TTT; Nghiem NM; Le PT; Vo QM; Day J; Rahman M; Le HM
    PLoS One; 2020; 15(5):e0233446. PubMed ID: 32433676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
    Latt NL; Yanny BT; Gharibian D; Gevorkyan R; Sahota AK
    World J Gastroenterol; 2017 Jul; 23(26):4759-4766. PubMed ID: 28765697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of the efficacy of antiviral therapy for hepatitis C virus infection by an ultrasensitive RT-PCR assay.
    Kinai E; Hanabusa H; Kato S
    J Med Virol; 2007 Aug; 79(8):1113-9. PubMed ID: 17596840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
    Shiffman ML; Suter F; Bacon BR; Nelson D; Harley H; Solá R; Shafran SD; Barange K; Lin A; Soman A; Zeuzem S;
    N Engl J Med; 2007 Jul; 357(2):124-34. PubMed ID: 17625124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
    Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
    J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
    Alqahtani S; Ozaras R; Isakov V; Wyles D; Ferenci P; Feld JJ; Calinas F; Gschwantler M; Gane E; Crawford D; Jacobson IM; Dumas EO; King M; Sulkowski M
    J Viral Hepat; 2017 Apr; 24(4):280-286. PubMed ID: 27935166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
    Naggie S; Fierer DS; Hughes MD; Kim AY; Luetkemeyer A; Vu V; Roa J; Rwema S; Brainard DM; McHutchison JG; Peters MG; Kiser JJ; Marks KM; Chung RT;
    Clin Infect Dis; 2019 Jul; 69(3):514-522. PubMed ID: 31220220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
    Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
    J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection.
    Aghemo A; Degasperi E; De Nicola S; Bono P; Orlandi A; D'Ambrosio R; Soffredini R; Perbellini R; Lunghi G; Colombo M
    Clin Gastroenterol Hepatol; 2016 Sep; 14(9):1331-6. PubMed ID: 27046484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
    Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment.
    Thornton K; Deming P; Manch RA; Moore A; Kohli A; Gish R; Sussman NL; Khaderi S; Scott J; Mera J; Box T; Qualls C; Sedillo M; Arora S
    Hepatol Int; 2016 Jul; 10(4):624-31. PubMed ID: 27098355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Tabernilla A; Grandal M; Pernas B; Castro-Iglesias A; Rodríguez-Osorio I; Mena A; Delgado M; Cid P; Pedreira JD; Poveda E
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):781-785. PubMed ID: 28410351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Campos-Varela I; Agudelo EZ; Sarkar M; Roberts JP; Terrault NA
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
    Flower B; Hung LM; Mccabe L; Ansari MA; Le Ngoc C; Vo Thi T; Vu Thi Kim H; Nguyen Thi Ngoc P; Phuong LT; Quang VM; Dang Trong T; Le Thi T; Nguyen Bao T; Kingsley C; Smith D; Hoglund RM; Tarning J; Kestelyn E; Pett SL; van Doorn R; Van Nuil JI; Turner H; Thwaites GE; Barnes E; Rahman M; Walker AS; Day JN; Chau NVV; Cooke GS
    Elife; 2023 Jan; 12():. PubMed ID: 36622106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
    Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.
    Sarrazin C; Dierynck I; Cloherty G; Ghys A; Janssen K; Luo D; Witek J; Buti M; Picchio G; De Meyer S
    J Clin Microbiol; 2015 Apr; 53(4):1264-9. PubMed ID: 25653396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.
    Berg T; Sarrazin C; Herrmann E; Hinrichsen H; Gerlach T; Zachoval R; Wiedenmann B; Hopf U; Zeuzem S
    Hepatology; 2003 Mar; 37(3):600-9. PubMed ID: 12601358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy.
    Sarrazin C; Wedemeyer H; Cloherty G; Cohen DE; Chevaliez S; Herman C; Bernstein B; Pawlotsky JM
    J Virol Methods; 2015 Mar; 214():29-32. PubMed ID: 25528998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.